Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash & Equivalents (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed Cash & Equivalents for 3 consecutive years, with $109.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 71.02% to $109.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $109.5 million through Dec 2025, up 71.02% year-over-year, with the annual reading at $109.5 million for FY2025, 71.02% up from the prior year.
  • Cash & Equivalents hit $109.5 million in Q4 2025 for Camp4 Therapeutics, up from $75.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $109.5 million in Q4 2025 to a low of $2.5 million in Q3 2024.
  • Historically, Cash & Equivalents has averaged $53.6 million across 3 years, with a median of $49.9 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 94.99% in 2024 and later soared 2878.64% in 2025.
  • Year by year, Cash & Equivalents stood at $38.4 million in 2023, then skyrocketed by 66.86% to $64.0 million in 2024, then soared by 71.02% to $109.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for CAMP at $109.5 million in Q4 2025, $75.3 million in Q3 2025, and $39.1 million in Q2 2025.